Clinical Trials
94 trialsSUNRAY-01
Eli Lilly and Company
ALKAZAR
Nuvalent Inc.
REVIVE
AstraZeneca
REZILIENT3
Taiho Oncology, Inc.
TRIDENT-1
Turning Point Therapeutics, Inc.
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Seagen Inc.
Smartphone-based Telerehabilitation Versus Home-based Inspiratory Muscle Training After Lung Resection in High-risk Patients
Pusan National University Hospital
ARIAN
Fundación GECP
REVOLU
University Hospital, Bordeaux
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
LADOGA
AstraZeneca
NADIM-ADJUVANT
Fundación GECP
NIVIPI-Brain
Fundación GECP
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
LIBRETTO-001
Eli Lilly and Company
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Iovance Biotherapeutics, Inc.
Lung Cancer Screening CT for Firefighters
University of California, San Francisco
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients
Instituto Nacional de Cancerologia de Mexico
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Pfizer
AcceleRET-Lung
Hoffmann-La Roche
LOTOS
AstraZeneca
Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers
H. Lee Moffitt Cancer Center and Research Institute
ASPECT
University of Aarhus
VALOR
VA Office of Research and Development
LIBRETTO-121
Eli Lilly and Company
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
TELESCOPE-H
Rutgers, The State University of New Jersey
Lung Cancer Risk and Early Detection in Firefighters
Massachusetts General Hospital
FIRSTLUNG
Delfi Diagnostics Inc.
PALACE
Fundación GECP
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd.
SPSIPB vs SAPB for Thoracoscopic Surgery
Medipol University
Image - Navigated Resection of Lung Nodules
Navigation Sciences, Inc.
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
RenJi Hospital
ARROW
Hoffmann-La Roche
Early Intervention Strategies for Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Yale University
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
APOLO
Fundación GECP
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Ensuring Precision-Medicine Delivery for Veterans With Lung Cancer
Stanford University
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
FCS2
University of Washington
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Iovance Biotherapeutics, Inc.
PROACT
VA Office of Research and Development
Comparison Between Different Ways for Using Lidocaine During FB
Assiut University